Government caps on trade margins for 137 cancer medicines have not necessarily translated into lower prices for every patient.
The report describes families continuing to face high treatment bills, particularly for some patented medicines. It highlights pembrolizumab, an immunotherapy used for several cancers, as one example where the price remained unchanged despite a trade-margin cap.
The issue shows the difference between regulating parts of a medicine’s pricing chain and reducing the full cost a patient pays for treatment.
What the cap changes
A trade-margin cap limits how much intermediaries can add to a medicine’s price. It may reduce costs where those margins were contributing substantially to the final price.
But the cap does not necessarily change the underlying price set for a patented medicine. The report says an analysis of revised prices submitted by pharmaceutical companies found that several expensive formulations, especially patented medicines, had not become cheaper.
Even when a price falls, the reduction may be small compared with the total cost of treatment. Cancer care can also include surgery, chemotherapy, tests, supportive medicines and hospital expenses, so the cost of one drug is only part of the family’s financial burden.
A family’s treatment decision
The Indian Express report describes a patient diagnosed with an aggressive form of breast cancer whose family was told treatment could cost around ₹20 lakh. The family faced additional barriers because the patient lacked personal health insurance, and the hospital’s support arrangements did not cover the immunotherapy in the way they had hoped.
The example illustrates how a medicine may be medically available but difficult to afford. Patient assistance programmes can help some people, but eligibility rules and payment requirements may leave families covering substantial costs.
The report says the family still faced a price of ₹2.17 lakh per vial for pembrolizumab after the trade-margin cap. Individual treatment plans and prices can differ, so this reported case should not be taken as a universal bill.
Access and affordability are separate questions
A drug can be approved and stocked by hospitals while remaining financially out of reach for many patients. Insurance coverage, public assistance, hospital policies and manufacturer programmes can all affect whether a patient can begin or continue treatment.
Patented medicines may be particularly challenging because their prices are not shaped by generic competition in the same way as older medicines. Governments may use several policy tools to address affordability, but each has different effects on manufacturers, hospitals and patients.
The report also describes families drawing on savings or borrowing money to manage treatment. Such decisions can place pressure on households already dealing with a serious illness.
What patients and policymakers need to know
The findings raise questions about how policy success should be measured. Counting the number of medicines covered by a cap is one measure; tracking the final out-of-pocket price paid by patients is another.
Clearer public information about actual prices, assistance programmes and insurance coverage could help families understand their options. Policymakers may also need to examine why some capped medicines remain unchanged in price and whether additional measures are needed.
The story does not mean that price caps have no effect. It shows that the effect may vary by medicine and that some families may see little relief. Any changes to treatment should be discussed with a qualified healthcare professional, who can explain clinically appropriate options and available support.